BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval for Advanced Esophageal Squamous Cell Carcinoma

 BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval for Advanced Esophageal Squamous Cell Carcinoma

Shots:

  • The US FDA’s approval is based on P-III ATTRACTION-3 study assessing Opdivo (240mg by IV infusion over 30min, q2w) vs taxane CT (docetaxel/paclitaxel) in patients with unresectable advanced, recurrent or ESCC, refractory/ intolerant to at least one prior fluoropyrimidine & platinum-based CT
  • Opdivo is the first approved immunotherapy in this setting regardless of tumor PD-L1 expression level. Efficacy results: OS (10.9 vs 8.4mos.); ORR (19.3% vs 21.5%); median PFS (1.7 vs 3.4mos.)
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response

Click here to read full press release/ article | Ref: Business wire | Image: BMS

Related News: ONO and BMS Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) in Japan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post